224 related articles for article (PubMed ID: 28485171)
1. BRAF inhibitors: efficacious and tolerable in BRAF-mutant acral and mucosal melanoma.
Bai X; Mao LL; Chi ZH; Sheng XN; Cui CL; Kong Y; Dai J; Wang X; Li SM; Tang BX; Lian B; Zhou L; Yan XQ; Guo J; Si L
Neoplasma; 2017; 64(4):626-632. PubMed ID: 28485171
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data.
Czirbesz K; Gorka E; Balatoni T; Pánczél G; Melegh K; Kovács P; Gézsi A; Liszkay G
Pathol Oncol Res; 2019 Jan; 25(1):45-50. PubMed ID: 28963614
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV
Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930
[TBL] [Abstract][Full Text] [Related]
5. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G; McQuade JL; Panka DJ; Hudgens CW; Amin-Mansour A; Mu XJ; Bahl S; Jané-Valbuena J; Wani KM; Reuben A; Creasy CA; Jiang H; Cooper ZA; Roszik J; Bassett RL; Joon AY; Simpson LM; Mouton RD; Glitza IC; Patel SP; Hwu WJ; Amaria RN; Diab A; Hwu P; Lazar AJ; Wargo JA; Garraway LA; Tetzlaff MT; Sullivan RJ; Kim KB; Davies MA
JAMA Oncol; 2016 Aug; 2(8):1056-64. PubMed ID: 27124486
[TBL] [Abstract][Full Text] [Related]
6. Outcome of combination therapy using BRAF and MEK inhibitors among Asian patients with advanced melanoma: An analysis of 112 cases.
Fujisawa Y; Ito T; Kato H; Irie H; Kaji T; Maekawa T; Asai J; Yamamoto Y; Fujimura T; Nakai Y; Yasuda M; Matsuyama K; Muto I; Matsushita S; Uchi H; Nakamura Y; Uehara J; Yoshino K
Eur J Cancer; 2021 Mar; 145():210-220. PubMed ID: 33503528
[TBL] [Abstract][Full Text] [Related]
7. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry.
Cho J; Ahn S; Yoo KH; Kim JH; Choi SH; Jang KT; Lee J
Invest New Drugs; 2016 Dec; 34(6):677-684. PubMed ID: 27491654
[TBL] [Abstract][Full Text] [Related]
8. Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma.
Alexander M; Mellor JD; McArthur G; Kee D
Med J Aust; 2014 Jul; 201(1):49-53. PubMed ID: 24999899
[TBL] [Abstract][Full Text] [Related]
9. Optimal strategy in managing advanced melanoma.
Uchi H
J Dermatol; 2024 Mar; 51(3):324-334. PubMed ID: 38087810
[TBL] [Abstract][Full Text] [Related]
10. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
11. c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis.
Steeb T; Wessely A; Petzold A; Kohl C; Erdmann M; Berking C; Heppt MV
Eur J Cancer; 2021 Nov; 157():348-357. PubMed ID: 34562816
[TBL] [Abstract][Full Text] [Related]
12. Upcoming strategies for the treatment of metastatic melanoma.
Spagnolo F; Queirolo P
Arch Dermatol Res; 2012 Apr; 304(3):177-84. PubMed ID: 22350184
[TBL] [Abstract][Full Text] [Related]
13. Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.
Geukes Foppen MH; Boogerd W; Blank CU; van Thienen JV; Haanen JB; Brandsma D
Melanoma Res; 2018 Apr; 28(2):126-133. PubMed ID: 29356790
[TBL] [Abstract][Full Text] [Related]
14. Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study.
Si L; Zhang X; Shu Y; Pan H; Wu D; Liu J; Mao L; Wang X; Wen X; Gu Y; Zhu L; Lan S; Cai X; Diede SJ; Dai H; Niu C; Li J; Guo J
Front Immunol; 2022; 13():882471. PubMed ID: 36304457
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of rechallenge with BRAF inhibition therapy in patients with advanced BRAFV600 mutant melanoma.
Viñal D; Martinez D; Espinosa E
Clin Transl Oncol; 2019 Aug; 21(8):1061-1066. PubMed ID: 30607792
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of distant metastasis-free interval in patients with relapsed melanoma treated with BRAF with or without MEK inhibitors.
Bafaloukos D; Papaxoinis G; Linardou H; Diamantopoulos P; Laskarakis A; Anastasopoulou A; Sergentanis TN; Tarampikou A; Tsoutsos D; Gogas H
Melanoma Res; 2019 Aug; 29(4):428-434. PubMed ID: 30601377
[TBL] [Abstract][Full Text] [Related]
17. Long-term effects of BRAF inhibitors in melanoma treatment: friend or foe?
Sloot S; Fedorenko IV; Smalley KS; Gibney GT
Expert Opin Pharmacother; 2014 Apr; 15(5):589-92. PubMed ID: 24456413
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.
Carlos G; Anforth R; Clements A; Menzies AM; Carlino MS; Chou S; Fernandez-Peñas P
JAMA Dermatol; 2015 Oct; 151(10):1103-9. PubMed ID: 26200476
[TBL] [Abstract][Full Text] [Related]
19. Novel inhibitors in the treatment of metastatic melanoma.
Kalinsky K; Haluska FG
Expert Rev Anticancer Ther; 2007 May; 7(5):715-24. PubMed ID: 17492934
[TBL] [Abstract][Full Text] [Related]
20. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
